首頁 > 市場調查報告書 > 醫療設備

生技設備基因治療學和RNAi 核酸藥物

市場調查報告書

商品編碼

1484660

等溫核酸擴增技術的全球市場：市場規模和佔有率分析（依產品、技術、應用和最終用戶）、產業成長預測（截至2030年）

Isothermal Nucleic Acid Amplification Technology Market Size Report by Product, Technology, Application, End User - Global Industry Growth Forecast to 2030

出版日期: 2024年05月08日 | 出版商:

Prescient & Strategic Intelligence | 英文 260 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

市場概況

全球等溫核酸擴增技術（INAAT）市場2023年營收為44.255億美元，預計到2030年將達到81.594億美元，2024年至2030年複合年增長率為9.4%。這一增長的推動因素是分子檢測技術的使用大幅增加，因為結核病、肝炎和流感等傳染病的盛行率不斷上升，這些疾病是導致死亡的主要原因，尤其是在發展中國家。

重要見解

2023年，耗材品類預計將透過引領恆溫核酸擴增技術產業保持主導地位，佔70%的收入佔有率。這些試劑在診斷實驗室和主要醫療機構中的廣泛使用促成了這一優勢。

由於 COVID-19 等傳染病的新型診斷技術的研發投資增加，預計設備類別將出現最快的成長。

到2023年，醫院類別預計將佔INAAT產業60%的佔有率，並由於小型化POC設備的使用不斷增加而保持其主導地位。

由於患者數量的增加以及早期疾病檢測分子技術的採用，以及公共機構用於緩解傳染病的資金的支持，診斷中心預計將實現最高的複合年增長率。

到 2023 年，北美將佔市場約 45%，由於已建立的研究基礎設施和對基於核酸擴增的診斷的需求，預計該市場將出現強勁增長。高昂的人均醫療保健成本和對現場診斷的興趣正在推動北美市場的擴張。

到2023年，環介導擴增預計將佔INAAT產業銷售佔有率的40%，並繼續佔據主導地位。升級到 LAMP 技術可在等溫條件下實現高度定向、高生產率和快速的原位 DNA 製造流程。

本報告分析了全球等溫核酸擴增技術市場，提供了市場的基本結構、最新情況、主要推動和抑制因素以及全球、依地區和主要國家的市場規模前景（價值基礎、 2017 -2030），依產品、技術、應用和最終用戶劃分的詳細趨勢、市場競爭現狀以及主要公司概況。

The global isothermal nucleic acid amplification technology market generated revenue of USD 4,425.5 million in 2023 and is expected to witness a CAGR of 9.4% during 2024-2030, reaching USD 8,159.4 million by 2030. This growth is attributed to the significant increase in its usage as a molecular testing technique due to the rising prevalence of infectious diseases, including tuberculosis, hepatitis, and influenza, which are among the leading causes of death, particularly in developing countries.

Tuberculosis, hepatitis, and flu are diseases transmitted by way of infectious diseases in which the leading cause of death is mostly observed in underdeveloped countries.

a bewildering range of diagnostic tests combined with an increasing number of Emergency Use Authorizations for CLIA-waived tests are spurring the development of the isothermal nucleic acid amplification technology market. These tests being free of complex procedures, lesser chances of error, and being able to personalize the dose on patients are a few instances of why these tests remain so popular.

These technologies have various uses such as gene manipulation that is done with recombinant DNA and similar molecular biology practices. It is a new way to detect prepare and analyze a small number of nucleic acids containing DNA or RNA that enter into cells.

Historically, there has never been a life history that was free from infectious diseases and this has continued to be a major cause of death and disability. With the increasing incidences of communicable diseases around the world which as weighty factors in the market expansion, this field is seeing major growth nowadays.

Key Insights

In 2023, the consumables category led the isothermal nucleic acid amplification technology industry, with a 70% revenue share, projected to uphold supremacy.

The wide use of reagents in diagnostic laboratories and major healthcare settings contributes to this supremacy.

Obtainability of polymerases with high strand displacement abilities further boosts demand for consumables.

Companies are making numerous reagents to sense communicable diseases, confronting the growing occurrence.

Increasing cases of cardiovascular illnesses, diabetes, and cholesterol-linked illnesses drive the growth of convenient POC diagnostic devices.

The instruments category is expected to show the fastest growth due to increased R&D investments in novel diagnostic techniques for infectious diseases like COVID-19.

In 2023, the hospital's category led with a 60% share in the INAAT industry, projected to uphold supremacy because of the augmented usage of miniaturized POC instruments.

Increased throughput and automation capabilities of INAAT technologies for processing large sample volumes are expected to drive segment growth.

Diagnostic centers forecast the highest CAGR due to rising numbers and the adoption of molecular techniques for early disease detection, supported by funding from public agencies for infectious disease mitigation.

North America held around 45% of the market in 2023, poised for robust growth due to established research infrastructure and demand for nucleic-acid-amplification-based diagnostics.

High per capita healthcare spending and interest in point-of-care diagnostics drive market expansion in North America.

In 2023, loop-mediated amplification dominated the INAAT industry with a 40% revenue share, projected to uphold supremacy.

LAMP technology upgrades allow highly directive, productive, and fast in-situ DNA manufacturing process under isothermal conditions.

There recruitation of DNA polymerase and four primer adds protrusion of six different motifs on target DNA in DNA replication.

The kit is a microbial identification method which includes three types of detection techniques (lateral flow, agarose gel detection, and real-time fluorescence with intercalators)

LAMP against PCR's resistance to interactive molecules is that samples can be used even in the less purified form.

It has a potential for testing all RNA and DNA sequences at the same time and is capable of detecting both Zika and SARS-CoV-2 viruses in human specimens.

Chapter 1. Research Scope

1.1. Research Objectives
1.2. Market Definition
1.3. Analysis Period
1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by product
- 1.4.2. Market size breakdown, by technology
- 1.4.3. Market size breakdown, by application
- 1.4.4. Market size breakdown, by end user
- 1.4.5. Market size breakdown, by region
- 1.4.6. Market size breakdown, by country
1.5. Market Data Reporting Unit
- 1.5.1. Value
1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
2.2. Primary Research
2.3. Market Size Estimation
2.4. Data Triangulation
2.5. Currency Conversion Rates
2.6. Assumptions for the Study
2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
5.2. Impact of COVID-19
5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes

Chapter 6. Global Market

6.1. Overview
6.2. Market Revenue, by Product (2017-2030)
6.3. Market Revenue, by Technology (2017-2030)
6.4. Market Revenue, by Application (2017-2030)
6.5. Market Revenue, by End User (2017-2030)
6.6. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

7.1. Overview
7.2. Market Revenue, by Product (2017-2030)
7.3. Market Revenue, by Technology (2017-2030)
7.4. Market Revenue, by Application (2017-2030)
7.5. Market Revenue, by End User (2017-2030)
7.6. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

8.1. Overview
8.2. Market Revenue, by Product (2017-2030)
8.3. Market Revenue, by Technology (2017-2030)
8.4. Market Revenue, by Application (2017-2030)
8.5. Market Revenue, by End User (2017-2030)
8.6. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

9.1. Overview
9.2. Market Revenue, by Product (2017-2030)
9.3. Market Revenue, by Technology (2017-2030)
9.4. Market Revenue, by Application (2017-2030)
9.5. Market Revenue, by End User (2017-2030)
9.6. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

10.1. Overview
10.2. Market Revenue, by Product (2017-2030)
10.3. Market Revenue, by Technology (2017-2030)
10.4. Market Revenue, by Application (2017-2030)
10.5. Market Revenue, by End User (2017-2030)
10.6. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

11.1. Overview
11.2. Market Revenue, by Product (2017-2030)
11.3. Market Revenue, by Technology (2017-2030)
11.4. Market Revenue, by Application (2017-2030)
11.5. Market Revenue, by End User (2017-2030)
11.6. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

12.1. Overview
12.2. Market Revenue, by Product (2017-2030)
12.3. Market Revenue, by Technology (2017-2030)
12.4. Market Revenue, by Application (2017-2030)
12.5. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

13.1. Overview
13.2. Market Revenue, by Product (2017-2030)
13.3. Market Revenue, by Technology (2017-2030)
13.4. Market Revenue, by Application (2017-2030)
13.5. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

14.1. Overview
14.2. Market Revenue, by Product (2017-2030)
14.3. Market Revenue, by Technology (2017-2030)
14.4. Market Revenue, by Application (2017-2030)
14.5. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

15.1. Overview
15.2. Market Revenue, by Product (2017-2030)
15.3. Market Revenue, by Technology (2017-2030)
15.4. Market Revenue, by Application (2017-2030)
15.5. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

16.1. Overview
16.2. Market Revenue, by Product (2017-2030)
16.3. Market Revenue, by Technology (2017-2030)
16.4. Market Revenue, by Application (2017-2030)
16.5. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

17.1. Overview
17.2. Market Revenue, by Product (2017-2030)
17.3. Market Revenue, by Technology (2017-2030)
17.4. Market Revenue, by Application (2017-2030)
17.5. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

18.1. Overview
18.2. Market Revenue, by Product (2017-2030)
18.3. Market Revenue, by Technology (2017-2030)
18.4. Market Revenue, by Application (2017-2030)
18.5. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

19.1. Overview
19.2. Market Revenue, by Product (2017-2030)
19.3. Market Revenue, by Technology (2017-2030)
19.4. Market Revenue, by Application (2017-2030)
19.5. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

20.1. Overview
20.2. Market Revenue, by Product (2017-2030)
20.3. Market Revenue, by Technology (2017-2030)
20.4. Market Revenue, by Application (2017-2030)
20.5. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

21.1. Overview
21.2. Market Revenue, by Product (2017-2030)
21.3. Market Revenue, by Technology (2017-2030)
21.4. Market Revenue, by Application (2017-2030)
21.5. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

22.1. Overview
22.2. Market Revenue, by Product (2017-2030)
22.3. Market Revenue, by Technology (2017-2030)
22.4. Market Revenue, by Application (2017-2030)
22.5. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

23.1. Overview
23.2. Market Revenue, by Product (2017-2030)
23.3. Market Revenue, by Technology (2017-2030)
23.4. Market Revenue, by Application (2017-2030)
23.5. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

24.1. Overview
24.2. Market Revenue, by Product (2017-2030)
24.3. Market Revenue, by Technology (2017-2030)
24.4. Market Revenue, by Application (2017-2030)
24.5. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

25.1. Overview
25.2. Market Revenue, by Product (2017-2030)
25.3. Market Revenue, by Technology (2017-2030)
25.4. Market Revenue, by Application (2017-2030)
25.5. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

26.1. Overview
26.2. Market Revenue, by Product (2017-2030)
26.3. Market Revenue, by Technology (2017-2030)
26.4. Market Revenue, by Application (2017-2030)
26.5. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

27.1. Overview
27.2. Market Revenue, by Product (2017-2030)
27.3. Market Revenue, by Technology (2017-2030)
27.4. Market Revenue, by Application (2017-2030)
27.5. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

28.1. Overview
28.2. Market Revenue, by Product (2017-2030)
28.3. Market Revenue, by Technology (2017-2030)
28.4. Market Revenue, by Application (2017-2030)
28.5. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

29.1. List of Market Players and their Offerings
29.2. Competitive Benchmarking of Key Players
29.3. Product Benchmarking of Key Players
29.4. Recent Strategic Developments

Chapter 30. Company Profiles

30.1. Becton, Dickinson and Company
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
30.2. QIAGEN N.V.
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
30.3. Quidel Corporation
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
30.4. bioMerieux SA
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
30.5. Abbott Laboratories
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
30.6. Meridian Bioscience Inc.
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.6.3. Key financial summary
30.7. Thermo Fisher Scientific Inc.
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.7.3. Key financial summary
30.8. Atila Biosystems
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
- 30.8.3. Key financial summary
30.9. Grifols S.A.
- 30.9.1. Business overview
- 30.9.2. Product and service offerings
- 30.9.3. Key financial summary
30.10. Eiken Chemical Co. Ltd.
- 30.10.1. Business overview
- 30.10.2. Product and service offerings
- 30.10.3. Key financial summary